| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | 31.12.02 |
| PATENT TITLE |
CARK protein and nucleic acid molecules and uses therefor |
| PATENT ABSTRACT |
The invention provides isolated nucleic acids molecules, designated CARK nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing CARK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a CARK gene has been introduced or disrupted. The invention still further provides isolated CARK proteins, fusion proteins, antigenic peptides and anti-CARK antibodies. Diagnostic methods utilizing compositions of the invention are also provided. |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | December 10, 1999 |
| PATENT REFERENCES CITED |
Sptrembl Database Accession No. 017055, dated Jan. 01, 1998.* Baumeister, A. et al. "Accumulation of muscle Ankyrin repeat protein transcript reveals local activation of primary myotube end compartments during muscle morphogenesis," J. Cell. Biol., 139(5): 1231-1242 (1997). Bevan, M. et al. "Analysis of 1.9 Mb of contiguous sequence from chromosome 4 of Arabidopsis thaliana," Nature, 391 (6666):485-488 (1988). Cairns,B.R., et al. "Order of action of components in the yeast pheromone response pathway revealed with a dominant allele of the STE11 kinase and the multiple phosphorylation of the STE7 kinase," Genes Dev., 6 (7):1305-1318 (1992). Cannon, J.F. et al. "Characterization of Saccharomyces cerevisiae genes encoding subunits of cyclic AMP-dependent protein kinase," Mol. Cell. Biol., 7 (8):2653-2663 (1987). Sicheri, F. et al. "Crystal structure of the Src family tyrosine kinase Hck," Nature, 385:602-609 (1997). Costigan,C., et al. "A synthetic lethal screen identifies SLK1, a novel protein kinase homolog implicated in yeast cell morphogenesis and cell growth," Mol. Cell. Biol., 12 (3):1162-1178 (1992). Delcommenne, M. et al. "Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase," PNAS USA, 95:11211-11216 (1998). Eber, S.W., et al. "Ankyrin-1 mutations are a major cause of dominant and recessive hereditary spherocytosis," Nat. Genet., 13 (2):214-218 (1996). Ebina,Y., et al. "The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling," Cell, 40 (4): 747-758 (1985). Fearon,K. et al. "Structure and function of MRP20 and MRP49, the nuclear genes for two proteins of the 54 S subunit of the yeast mitochondrial ribosome," J. Biol. Chem., 267 (8): 5162-5170 (1992). Feng,X.-H., et al. "Cloning and characterization of a novel member of protein kinase family from soybean," Biochim. Biophys. Acta., 1172: 200-204 (1993). Gallagher, P.G. et al. "An alternate promoter directs expression of a truncated, muscle-specific isoform of the human ankyrin 1 gene," J. Biol. Chem., 273(3):1339-1348 (1998). Goto, K. et al. "A 104-kDa diacylglycerol kinase containing ankyrin-like repeats localizes in the cell nucleus," PNAS USA, 93: 11196-11201 (1996). Hsu, S-C. et al. "Modulation of transcriptional regulation by LEF-1 in response to Wnt-1 signaling and association with beta-catenin," Mol. Cell. Biol., 18(8): 4807-4818 (1998). Hubbard,S.R., et al. "Crystal structure of the tyrosine kinase domain of the human insulin receptor," Nature, 372 (6508): 746-753 (1994). Hwang,D.M., et al. "Analysis of expressed sequence tags from a fetal human heart cDNA library," Genomics, 30 (2): 293-298 (1995). Irie,K., et al. "A new protein kinase, SSP31, modulating the SMP3 gene-product involved in plasmid maintenance in Saccharomyces cerevisiae," Gene, 108 (1): 139-144 (1991). Jeyaseelan, R et al. "A novel cardiac-restricted target for doxorubicin: Carp, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes," J. Biol. Chem., 272(5):22800-22808 (1997). Johnston,M., et al. "Complete nucleotide sequence of Saccharomyces cerevisiae chromosome VIII," Science, 265 (5181): 2077-2082 (1984). Kariya, K et al. "An enhancer Core Element Mediates Stimulation of the Rat .beta.-Myosin Heavy Chain Promoter by an .alpha..sub.1 Adrenergic Agonist and Activated .beta.-Protein Kinase C in Hypertrophy of Cardiac Myocytes,"The Journal Of Biological Chemistry, 269 (5) 3775-3782( 1993). Katoh,M., et al. "Cloning and characterization of MST, a novel (putative) serine/threonine kinase with SH3 domain," Oncogene, 10 (7): 1447-1451 (1995). Laidlaw,S.M., et al. "Fowlpox virus encodes nonessential homologs of cellular alpha-SNAP, PC-1, and an orphan human homolog of a secreted nematode protein," J. Virol., 72 (8): 6742-6751 (1998). Lambert,S., et al. "cDNA sequence for human erythrocyte ankyrin," Proc. Natl. Acad. Sci. U.S.A., 87 (5): 1730-1734 (1990). Lee,K.S. et al. "Dominant mutations in a gene encoding a putative protein kinase (BCK1) bypass the requirement for a Saccharomyces cerevisiae protein kinase C homolog," Mol. Cell. Biol., 12 (1): 172-182 (1992). Lisziewicz,J., et al. "Isolation and nucleotide sequence of a Saccharomyces cerevisiae protein kinase gene suppressing the cell cycle start mutation cdc25," J. Biol. Chem., 262 (6): 2549-2553 (1987). Lux,S.E., et al. "Analysis of cDNA for human erythrocyte ankyrin indicates a repeated structure with homology to tissue-differentiation and cell-cycle control proteins," Nature, 344 (6261): 36-42 (1990). Miosga,T., et al. "Sequence and function analysis of a 9.74 kb fragment of Saccharomyces cerevisiae chromosome X including the BCK1 gene," Yeast, 10 (11): 1481-1488 (1994). Mohammadi,M., et al. "Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism," Cell, 86 (4): 577-587 (1996). Novak, A. et al. "Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways," PNAS USA, 95: 4374-4379 (1998). Otsuka,A.J., et al. "An ankyrin-related gene (unc-44) is necessary for proper axonal guidance in Caenorhabditis elegans," J. Cell Biol., 129 (4): 1081-1092 (1995). Otto,E., et al. "Isolation and characterization of cDNAs encoding human brain ankyrins reveal a family of alternatively spliced genes," J. Cell Biol., 114 (2): 241-253 (1991). Percival-Smith,A. et al. "Characterization and mutational analysis of a cluster of three genes expressed preferentially during sporulation of Saccharomyces cerevisiae," Mol. Cell. Biol., 6 (7): 2443-2451 (1986). Radeva, G. et al. "Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression," J. Biol. Chem., 272(21): 13937-13944 (1997). Rhodes,N., et al. "STE11 is a protein kinase required for cell-type-specific transcription and signal transduction in yeast," Genes Dev., 4 (11): 1862-1874 (1990). Russo,A.A., et al. "Structural basis of cyclin-dependent kinase activation by phosphorylation," Nat. Struct. Biol., 3 (8): 696-700 (1996). Saito, H. et al. "Regulation of a novel gene encoding a lysyl oxidase-related protein in cellular adhesion and senescence," J. Biol. Chem., 272(13):8157-8160 (1997). Sheffield, V.C. et al. "Identification of a complex congenital heart defect susceptibility locus by using DNA pooling and shared segment analysis," Human Molecular Genetics, 6(1); 117-121 (1997). Sivasubramanian, N. et al., Cardiac myotrophin exhibits rel/NF-kB interacting activity in vitro, J. Biol. Chem., 271(5): 2812-2816 (1996). Somers, S.S. et al. "Comparison of transforming growth factor beta and a human tumour-derived suppressor factor," Cancer Immunology Immunotherapy, 33:217-22 (1991). Tan,J.L. et al. "Developmentally regulated protein-tyrosine kinase genes in Dictyostelium discoideum," Mol. Cell. Biol., 10: 3578-3583 (1990). Tanaka,T., et al. "Construction of a Normalized Directionally Cloned cDNA Library from Adult Heart and Analysis of 3040 Clones by Partial Sequencing," Genomics, 35: 231-235 (1996). Tse,W.T., et al. Isolation and chromosomal localization of a novel nonerythroid ankyrin genes,' Genomics, 10 (4): 858-866 (1991). Toda,T., et al. "Three different genes in S.cerevisiae encode the catalytic subunits of the cAMP-dependent protein kinase," Cell, 50: 277-287 (1987). Jeffrey, P.D. et al. "Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex," Nature, 376:313-320 (1995). Vandenbol,M., et al. "Sequencing and analysis of a 20.5 kb DNA segment located on the left arm of yeast chromosome XI," Yeast, 10 Suppl A: S25-S33 (1994). Xu,W., et al. "Three-dimensional structure of the tyrosine kinase c-Src," Nature, 385 (6617): 595-602 (1997). White,R.A., et al. "Murine erythrocyte ankyrin cDNA: highly conserved regions of the regulatory domain," Mamm. Genome,3 (5),: 281-285 (1992). Wilson,R., et al. "2.2 Mb of contiguous nucleotide sequence from chromosome III of C. elegans," Nature, 368 (6466): 32-38 (1994). Wu,L.C., et al. "Identification of a RING protein that can interact in vivo with the BRCA1 gene product," Nature Genet., 14 (4): 430-440 (1996). Wu,C., et al. "Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity," J. Biol. Chem., 273(1): 528-536 (1998). Zou, Y. et al. "CARP, a cardiac ankyrin repeat protein, is downstream in the Nkx2-5 homeobox gene pathway," Development, 124(4); 793-804 (1997). Jeyaseelan, R. et al., "A novel cardiac-restricted target for doxorubicin; Carp, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes," J Biol Chem, 272(36):22800-8 (1997). Database Trembl., ac: q9y2v6, (1999) Wei, Y.J. et al., "Hypothetical 92.9 kD protein," XP002136301. Zou, Y et al., "CARP, a cardiac ankyrin repeat protein, is downstream in the NKX2-5 homeobox gene pathway," Development, 124:793-804 (1997). Copy of Blast.RTM. search (Yeast database) using the CARP2 amino acid sequence; Blast vs. Prot. Patent, Nov. 17, 1999. Copy of Blast.RTM. search (Yeast database) using the CARP2 kinase domain amino acid sequence; Blast vs. Prot. Patent Nov. 17, 1999. Copy of Blast.RTM. search (NRP database) using the CARP2-prot amino acid sequence, Blast vs. Prot. Patent, Nov. 17, 1999. Copy of Blast.RTM. search (NRP database) using the CARP2 kinase domain amino acid sequence; Blast vs. Prot. Patent, Nov. 17, 1999. Copy of Blast.RTM. search (NRP database) using the CARP2 kinase domain amino acid sequences; Blast vs. Prot. Patent Nov. 17, 1999. Copy of Blast.RTM. search(Patent-2/gsprot database) using the rat Cark protein amino acid sequence; Blast vs. Prot. Patent., Nov. 17, 1999. Copy of Blast.RTM. search (Patent-2/Patent + DbPreviewNuc database) using The rat Cark cDNA nucleotide sequence; Blast vs. Prot. Patent, Nov. 17, 1999. Copy of Blast.RTM. search (Patent-2/gsnuc database) using the rat Cark cDNA nucleotide sequence; Blast vs. Nuc.Patent, Nov. 17, 1999. Copy of Blast.RTM. search (NRN/nuc database) using the rat Cark cDNA nucleotide sequence; Blast vs. Nuc. Patent, Nov. 17, 1999. Copy of Blast.RTM. search (NRP/protot database) using the rat Cark protein amino acid sequence; Blast vs. Prot, Nov. 17, 1999. GenBank Accession No. 1942427, Chain A, Cyclin A--Cyclin-Dependent Kinase 2 Complex; Jeffrey,P.D.; 1998. GenBank Accession No. 1942625, Chain A, Phosphorylated Cyclin-Dependent Kinase-2 Bound To Cyclin A, Russo,A.A.; 1998. GenBank Accession No. 2194103, Chain A, Src Family Kinase Hck-Amp-Pnp Complex, Sicheri,F.; 1998. GenBank Accession No. 2392334; chain A, crystal structure of the tyrosine-protein kinase domain of fibroblast growth factor receptor 1; Mohammadi,M.; 1998. GenBank Accession No. OKBYC1; Protein Kinase (EC 2.7.1.37), Camp-dependent, catalytic chain 1-yeast; Lisziewicz,J.; 1996. GenBank Accession No. 2392337 for crystal structure of human tyrosine-protein kinase c-src; Xu,W , 1997. GenBank Accession No. 999510 for insulin receptor (tyrosine kinase domain) mutant with cys 981 replaced by ser and tyr 984 replaced by phe; Ebina,Y.; 1994. GenBank Accession No. A35670; Protein-tyrosine kinase (EC 2.7.1.112) l-slime mold (dictyostelium discoideum); Camble,R ; 1999. GenBank Accession No. AA758546; ah70b01.sl Soares_testis_NHT Homo sapiens cDNA clone 1320937 3', mRNA sequence; NCI-CGAP; 1998. GenBank Accession No. AA389675, M186 Fetal heart, Lambda ZAP Express Homo sapiens cDNA 5'; Hwang,D.M., 1997. GenBank Accession No. AA938871; OP74ALL.S1 Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone image: 1582556 3'; NCI-CGAP; 1998. GenBank Accession No. 2781357, F2401.13; Shinn,P.; 1997. GenBank Accession No. AF024491; Caenorhabditis elegans cosmid C24A1; Connell,M.; 1997. GenBank Accession No. AF068261; Rattus norvegicus pancreatic serine threonine kinase mRNA, Miao, N.; 1998. GenBank Accession No. AI040439; ow 16c03.x1 Soares_parathyroid_rumor_NbHPA Homo sapiens cDNA clone image: 1646980 3' similar to WP:C24A1.3 CE08335; NCI-GCAP; 1998. GenBank Accession No. AI289394, qw2Ih08.x1 NCI_CGAP_Ut4 Homo sapiens cDNA clone image:1991775 3'; NCI-GCAP; 1998. GenBank Accession No. AI333762; qp98h10.x1 Soares_fetal_lung_NbHLI9W Homo sapiens cDNA clone image: I931107 3' similar to WP:C24A1.3 CE08335; NCI-CGAP; 1998. GenBank Accession No. AI375137; tc09g12.x1 Soares_NhHMPu_S1 Homo sapiens cDNA clone image: 2063398 3'similar to WP:C24A1 3 CE08335; NCI-CGAP; 1999. GenBank Accession No. AI377988; te61c04.x1 Soares_NFL_T_GBC_S1 Homo sapiens Sapiens cDNA clone image: 2091174 3'; NCI-CGAP; 1999. GenBank Accession No. AJ006408; Fowlpox virus strain ank2, ank3, snap, cell/dnasell and pcl genes; Skinner,M.A ; 1999. GenBank Accession No. CAA20048; Purative protein; Koetter,P ; 1999. GenBank Accession No. AQ242835; HS_2061_A1_G12_T7 CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate =2061 Col=23 Row=M; Mahairas.G. G.: 1998. GenBank Accession No. B35049; Ankyrin 1, erythrocyte form 3--human; Mahairas,G.G.; 1997. GenBank Accession No. C03950; Human heart cDNA (YNakamura) Homo sapiens cDNA clone 3NHC2459; Tanaka, T.: 1996. GenBank Accession No. D10389 ; Yeast DNA for Ssp31 protein kinase; Araki,H.; 1999. GenBank Accession No. M17074; Yeast (S. cerevisiae) cAMP-dependent kinase subunit (TPK3) gene; Toda,T., 1994. GenBank Accession No. M33784, D discoideum protein-tyrosine kinase-2 (DPYK2) mRNA; Tan,J.L ; 1994. GenBank Accession No. M33785; D.discoideum protein-tyrosine kinase-1 (DPYKI) mRNA; Tan,J.L ; 1994. GenBank Accession No. M67449; Glycine max protein kinase (PK6) mRNA, complete cds; Feng,X.H., 1994. GenBank Accession No. P05986; Camp dependent protein kinase type 3 (PKA 3); Toda,T.; 1999. GenBank Accession No. P06244; Camp-dependent protein kinase type 1 (PKA 1) (CDC25 suppressing protein kinase) (PK-25); Toda,T., 1999. GenBank Accession No. P08458; Sporulation-specific protein 1; Friesen,H.; 2000. GenBank Accession No. P16157; Ankyrin R (Ankyrins 2.1 and 2.2) (Erythrocyte ankyrin); Lux,S.E.; 2000. GenBank Accession No. P18160; Non-receptor tyrosine kinase spore lysis A (Tyrosine-protein kinase 1); Nuckolls,G.H.; 2000. GenBank Accession No. P23561; Serine/Threonine-protein kinase STE11; Rhodes,N.; 2000. GenBank Accession No. P38692; Serine/Threonine-protein kinase NRK1 (N-rich kinase 1); Fukami,Y.; 1999. GenBank Accession No. Q01389; Serine/Threonine protein kinase BCK1/SLK1/SSP31; Costigan,C.; 2000. GenBank Accession No. Q01485; Ankyrin, brain variant 2 (Ankyrin B) (Ankyrin, Nonery throid); Otto,E.; 1998. GenBank Accession No. Q02357; Ankyrin; White,R.A.; 2000. GenBank Accession No. X16609; Human mRNA for ankyrin (variant 2.1); Lux,S.E.; 1999. GenBank Accession No. X56958; Homo sapiens mRNA for ankyrin, Brank-2 protein; Otto,E.; 1999. GenBank Accession No. X60227; S.cerevisiae BCK1 gene for protein kinase; Levin,D.E.; 1999. GenBank Accession No. Z48615; H.sapiens MST mRNA for serine/threonine kinase; Karoh,M.; 1999. GenBank Accession No. R57737; F5349 fetal Heart Homo sapiens cDNA clone F5349 5' end; Hwang,D.M.; 1995. GenBank Accession No. Z97337, Arabidopsis thaliana DNA chromosome 4, ESSA I contig fragment No. 2; Bevan,M.; 1999. GenBank Accession No. Z98551; Plasmodium falciparum MAL3P6; Bowman,S.; 2000. GenBank Accession No. S51380; Protein kinase STE11 (EC 2.7.1.-)--yeast; Chang,Y.N.; 1993. GenBank Accession No. U01064; Dictyostelium discoideum AX2 protein tyrosine kinase mRNA; Adler,K.; 1996. GenBank Accession No. U21734; Caenorhabditis Elegans ankyrin-related protein UNC-44 (unc-44) gene; Otsuka,A.J.; 1996. GenBank Accession No. U39847; Caenorhabditis Elegans AO13 ankyrin, AO66 ankyrin and AO49 ankyrin (unc-44) gene, three alternatively spliced forms; Otsuka,A.J.; 1997. GenBank Accession No. U50071; Caenorhabditis Elegans cosmid B0350; Wilson,R.; 1996. GenBank Accession No. U65916; Ramus Norvegicus ankyrin mRNA, membrane binding domain; Cosentino,M.T.; 1997. GenBank Accession No. U76638; Human BRCA1-associated RING domain protein (BARD1) mRNA; Wu,L C ; 1996. GenBank Accession No. AAB70312; contains similarity to ankyrin repeats and protein kinase motifs; Connell,M.; 1997. GenBank Accession No. AF116826, Homo sapiens clone HH498 putative protein-tyrosine kinase mRNA, complete cds; Wei,Y.J.; 1999. GenBank Accession No. AF116826_1; putative protein-tyrosine kinase; Wei,Y J.; 1999 |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
What is claimed: 1. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:2. 2. An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:2. 3. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:8. 4. An isolated polypeptide consisting of the amino acid sequence of SEQ ID NO:8. 5. An isolated polypeptide which is encoded by the nucleotide sequence contained in the plasmid deposited with ATCC as Accession Number PTA-1530. 6. An isolated cardiac-related ankyrin-repeat protein kineas polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule which hybridizes to a complement of a nucleic acid molecule consisting of SEQ ID NO:1, 3, 7 or 9, in 6.times.SSC at 45.degree. C., followed by one or more washes in 0.2.times.SSC, 0.1% SDS at 65.degree. C. 7. An isolated cardiac-related ankyrin-repeat protein kinase polypeptide consisting of an amino acid sequence encoded by a nucleic acid molecule which hybridizes To a complement of a nucleic acid molecule consisting of SEQ ID NO:1, 3, 7 or 9, in 6.times.SSC at 45.degree. C., followed by one or more washes in 0.2.times.SSC, 0.1% SDS at 65.degree. C. 8. An isolated cardiac-related ankyrin-repeat protein kinase polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 90% identical to The nucleotide sequence of SEQ ID NO:1, 3, 7 or 9. 9. An isolated cardiac-related ankyrin-repeat protein kitase polypeptide which is encoded by a nucleic acid molecule consisting of a nucleotide sequence which is at least 90% identical to the nucleotide sequence of SEQ ID NO:1, 3, 7 or 9. 10. An isolated cardiac-related ankyrin-repeat protein kinase polypeptide comprising an amino acid sequence which is at least 90% identical to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:8, wherein said percent identity is calculated using the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. 11. An isolated cardiac-related ankyrin-repeat protein Use polypeptide comprising an Ho acid sequence which is encoded by a nucleic acid molecule having 1-5% vice as compared to the nucleotide sequence of SEQ ID NO:1, 3, 7 or 9, wherein said 1-5% variance results in an amino acid substitution at a non-essential amino acid residue of the polypeptide. 12. An isolated polypeptide consisting of a; least 25 consecutive amino acid residues of the amino acid sequence of SEQ ID NO:2 or 8. 13. An isolated polypeptide comprising amino acid residues 463-716 of SEQ ID NO:2 or 8. 14. An isolated polypeptide consisting of at least 50 consecutive amino acid residues of the amino acid sequence of SEQ ID NO:2 or 8. 15. An isolated polypeptide consisting of at least 100 consecutive amino acid residues of the amino acid sequence of SEQ ID NO:2 or 8. 16. An isolated polypeptide consisting of at least 200 consecutive amino acid residues of the amino acid sequence of SEQ ID NO:2 or 8. 17. The isolated polypeptide of any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 further comprising heterologous amino acid sequences. -------------------------------------------------------------------------------- |
| PATENT DESCRIPTION |
BACKGROUND OF THE INVENTION Phosphate tightly associated with protein has been known since the late nineteenth century. Since then, a variety of covalent linkages of phosphate to proteins have been found. The most common involve esterification of phosphate to serine, threonine, and tyrosine with smaller amounts being linked to lysine, arginine, histidine, aspartic acid, glutamic acid, and cysteine. The occurrence of phosphorylated proteins implies the existence of one or more protein kinases capable of phosphorylating amino acid residues on proteins, and also of protein phosphatases capable of hydrolyzing phosphorylated amino acid residues on proteins. Protein kinases play critical roles in the regulation of biochemical and morphological changes associated with cellular growth and division (D'Urso, G. et al. (1990) Science 250: 786-791; Birchmeier. C. et al. (1993) Bioessays 15: 185-189). They serve as growth factor receptors and signal transducers and have been implicated in cellular transformation and malignancy (Hunter, T. et al. (1992) Cell 70: 375-387; Posada, J. et al. (1992) Mol. Biol. Cell 3: 583-592; Hunter, T. et al. (1994) Cell 79: 573-582). For example, protein kinases have been shown to participate in the transmission of signals from growth-factor receptors (Sturgill, T. W. et al. (1988) Nature 344: 715-718; Gomez, N. et al. (1991) Nature 353: 170-173), control of entry of cells into mitosis (Nurse, P. (1990) Nature 344: 503-508; Mailer, J. L. (1991) Curr. Opin. Cell Biol. 3: 269-275) and regulation of actin bundling (Husain-Chishti, A. et al. (1988) Nature 334: 718-721). Protein kinases can be divided into two main groups based on either amino acid sequence similarity or specificity for either serine/threonine or tyrosine residues. A small number of dual-specificity kinases are structurally like the serine/threonine-specific group. Within the broad classification, kinases can be further sub-divided into families whose members share a higher degree of catalytic domain amino acid sequence identity and also have similar biochemical properties. Most protein kinase family members also share structural features outside the kinase domain that reflect their particular cellular roles. These include regulatory domains that control kinase activity or interaction with other proteins (Hanks, S. K. et al. (1988) Science 241: 42-52). For example, kinases which contain ankyrin repeat domains have been identified, such as the Integrin-linked kinase (ILK). ILK is an ankyrin repeat containing serine-threonine protein kinase which interacts with integrin .beta..sub.1 and .beta..sub.3 heterodimeric transmembrane glycoprotein subunit cytoplasmic domains. Integrins communicate with cell surface and cytoplasmic molecules such as cytoskeletal and catalytic signaling proteins (Hannigan G. E. et al. (1981) Nature 379:91-96, Schwartz M. A. et al. (1995) Annu. Rev. Cell Dev. Biol. 11:549-599). Overexpression of ELK increases the expression of cyclin A, cyclin D.sub.1 and Cdk4 proteins by overriding the adhesion-dependent regulation of cell cycle progression through G.sub.1 into S phase. This activity suggests that ILK may be an important regulator of integrin-mediated cell cycle progression (Radeva G. et al. (1997) J. Biol. Chem. 272:13937-13944). Overexpression of ILK also stimulates fibronectin matrix assembly in epithelial cells (Wu C. et al. (1998) J. Biol Chem. 273:528-536). SUMMARY OF THE INVENTION The present invention is based, at least in part, on the discovery of novel ankyrin repeat containing kinases, referred herein as "Cardiac-related Ankyrin-Repeat Protein Kinase" ("CARK") nucleic acid and protein molecules. The CARK molecules of the present invention are useful as modulating agents for regulating a variety of cellular processes, e.g., cardiac cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding CARK proteins or biologically active portions thereof, as well as nucleic acid fragments suitable as primers or hybridization probes for the detection of CARK-encoding nucleic acids. In one embodiment, a CARK nucleic acid molecule of the invention is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or more identical to the nucleotide sequence (e.g., to the entire length of the nucleotide sequence) shown in SEQ ID NO:1 or 3 or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number PTA-1530, or a complement thereof. In one embodiment, a CARK nucleic acid molecule of the invention is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82%, 85%, 90%, 95%, 98%, or more identical to the nucleotide sequence (e.g., to the entire length of the nucleotide sequence) shown in SEQ ID NO:7 or 9 or the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number PTA-1530, or a complement thereof. In a preferred embodiment, the isolated nucleic acid molecule includes the nucleotide sequence shown SEQ ID NO:1 or 3, or a complement thereof. In another embodiment, the nucleic acid molecule includes SEQ ID NO:3 and nucleotides 1-47 of SEQ ID NO:1. In another embodiment, the nucleic acid molecule includes SEQ ID NO:3 and nucleotides 2553-3025 of SEQ ID NO:1. In another preferred embodiment, the nucleic acid molecule consists of the nucleotide sequence shown in SEQ ID NO:1 or 3. In another preferred embodiment, the nucleic acid molecule includes a fragment of at least 467 nucleotides (e.g., 467 contiguous nucleotides) of the nucleotide sequence of SEQ ID NO:1 or 3, or a complement thereof. In a preferred embodiment, the isolated nucleic acid molecule includes the nucleotide sequence shown SEQ ID NO:7 or 9, or a complement thereof. In another embodiment, the nucleic acid molecule includes SEQ ID NO:9 and nucleotides 1-60 of SEQ ID NO:7. In another embodiment, the nucleic acid molecule includes SEQ ID NO:9 and nucleotides 2566-3026 of SEQ ID NO:7. In another preferred embodiment, the nucleic acid molecule consists of the nucleotide sequence shown in SEQ ID NO:7 or 9. In another preferred embodiment, the nucleic acid molecule includes a fragment of at least 2962 nucleotides (e.g., 2962 contiguous nucleotides) of the nucleotide sequence of SEQ ID NO:7 or 9, or a complement thereof. In another embodiment, a CARK nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of SEQ ID NO:2 or 8, or an amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number PTA-1530. In a preferred embodiment, a CARK nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more homologous to the entire length of the amino acid sequence of SEQ ID NO:2, or the amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number PTA-1530. In another preferred embodiment, a CARK nucleic acid molecule includes a nucleotide sequence encoding a protein having an amino acid sequence at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 98% or more homologous to the entire length of the amino acid sequence of SEQ ID NO:8, or the amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number PTA-1530. In another preferred embodiment, an isolated nucleic acid molecule encodes the amino acid sequence of human CARK. In yet another preferred embodiment, the nucleic acid molecule includes a nucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO:2, or the amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number PTA-1530. In yet another preferred embodiment, the nucleic acid molecule is at least 467 nucleotides in length. In a further preferred embodiment, the nucleic acid molecule is at least 467 nucleotides in length and encodes a protein having a CARK activity (as described herein). In another preferred embodiment, an isolated nucleic acid molecule encodes the amino acid sequence of rat CARK. In yet another preferred embodiment, the nucleic acid molecule includes a nucleotide sequence encoding a protein having the amino acid sequence of SEQ ID NO:8, or the amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number PTA-1530. In yet another preferred embodiment, the nucleic acid molecule is at least 2962 nucleotides in length. In a further preferred embodiment, the nucleic acid molecule is at least 2962 nucleotides in length and encodes a protein having a CARK activity (as described herein). Another embodiment of the invention features nucleic acid molecules, preferably CARK nucleic acid molecules, which specifically detect CARK nucleic acid molecules relative to nucleic acid molecules encoding non-CARK proteins. For example, in one embodiment, such a nucleic acid molecule is at least 250-300, 300-350, 350-400, 400-450, 467, 467-500, 500-550, or 550-600, 600-800, 800-1000, 1000-1200, 1200-1400, 1400-1600, 1600-1800, 1800-2000, 2000-2400, 2400-2800, 2800-2900, 2962, or more nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising the nucleotide sequence shown in SEQ ID NO:1, 3, 7, or 9, or, the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number PTA-1530, or a complement thereof. In preferred embodiments, the nucleic acid molecules are at least 15 (e.g., contiguous) nucleotides in length and hybridize under stringent conditions to nucleotides 1-47, 94-294, 318-338, 1145-1364, 1833-1921, 2051-2267, 2290-2543, or 3018-3025 of SEQ ID NO:1. In other preferred embodiments, the nucleic acid molecules comprise nucleotides 1-47, 94-294, 318-338, 1145-1364, 1833-1921, 2051-2267, 2290-2543, or 3018-3025 of SEQ ID NO:1. In other preferred embodiments, the nucleic acid molecules consist of 20 nucleotides 1-47, 94-294, 318-338, 1145-1364, 1833-1921, 2051-2267, 2290-2543, or 3018-3025 of SEQ ID NO:1. In other preferred embodiments, the nucleic acid molecule encodes a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:2 or 8, or an amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number PTA-1530, wherein the nucleic acid molecule hybridizes to a nucleic acid molecule comprising SEQ ID NO:1 or 3, or SEQ ID NO:7 or 9, respectively, under stringent conditions. Another embodiment of the invention provides an isolated nucleic acid molecule which is antisense to a CARK nucleic acid molecule, e.g., the coding strand of a CARK nucleic acid molecule. Another aspect of the invention provides a vector comprising a CARK nucleic acid molecule. In certain embodiments, the vector is a recombinant expression vector. In another embodiment, the invention provides a host cell containing a vector of the invention. In yet another embodiment, the invention provides a host cell containing a nucleic acid molecule of the invention. The invention also provides a method for producing a protein, preferably a CARK protein, by culturing in a suitable medium, a host cell, e.g., a mammalian host cell such as a non-human mammalian cell, of the invention containing a recombinant expression vector, such that the protein is produced. Another aspect of this invention features isolated or recombinant CARK proteins and polypeptides. In one embodiment, the isolated protein, preferably a CARK protein, includes at least one ankyrin repeat domain, and preferably two, three, four, five, six, seven, eight, or, most preferably, nine or more ankyrin repeat domains. In another embodiment, the isolated protein, preferably a CARK protein, includes at least one protein kinase domain. In a preferred embodiment, the protein, preferably a CARK protein, includes at least one ankyrin repeat domain and preferably two, three, four, five, six, seven, eight, or, most preferably, nine or more ankyrin repeat domains, and has an amino acid sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 98% or more homologous to the amino acid sequence of SEQ ID NO:2 or 8, or the amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number PTA-1530. In another preferred embodiment, the protein, preferably a CARK protein, includes at least one protein kinase domain and has an amino acid sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 98% or more homologous to the amino acid sequence of SEQ ID NO:2 or 8, or the amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number PTA-1530. In yet another preferred embodiment, the protein, preferably a CARK protein, includes at least one ankyrin repeat domain and preferably two, three, four, five, six, seven, eight, or, most preferably, nine or more ankyrin repeat domains, at least one protein kinase domain, and has an amino acid sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 95%, 98% or more homologous to the amino acid sequence of SEQ ID NO:2 or 8, or the amino acid sequence encoded by the DNA insert of the plasmid deposited with ATCC as Accession Number PTA-1530. In another preferred embodiment, the protein, preferably a CARK protein, includes at least one ankyrin repeat domain and preferably two, three, four, five, six, seven, eight, or, most preferably, nine or more ankyrin repeat domains and has a CARK activity, as described herein. In yet another preferred embodiment, the protein, preferably a CARK protein, includes a protein kinase domain and has a CARK activity, as described herein. In a further preferred embodiment, the protein, preferably a CARK protein, includes at least one ankyrin repeat domain and preferably two, three, four, five, six, seven, eight, or, most preferably, nine or more ankyrin repeat domains, at least one protein kinase domain, and has a CARK activity, as described herein. In yet another preferred embodiment, the protein, preferably a CARK protein, includes at least one ankyrin repeat domain and preferably two, three, four, five, six, seven, eight, or, most preferably, nine or more ankyrin repeat domains and is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 7, or 9. In a further embodiment, the protein, preferably a CARK protein, includes at least one protein kinase domain and is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 7, or 9. In another preferred embodiment, the protein, preferably a CARK protein, includes at least one ankyrin repeat domain and preferably two, three, four, five, six, seven, eight, or, most preferably, nine or more ankyrin repeat domains, at least one protein kinase domain, and is encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 7, or 9. In another embodiment, the invention features fragments of the protein having the amino acid sequence of SEQ ID NO:2 or 8, wherein the fragment comprises at least 15 amino acids (e.g., contiguous amino acids) of the amino acid sequence of SEQ ID NO:2 or 8 or an amino acid sequence encoded by the DNA insert of the plasmid deposited with the ATCC as Accession Number PTA-1530. In another embodiment, the protein, preferably a CARK protein, has the amino acid sequence of SEQ ID NO:2 or 8. In another embodiment, the invention features an isolated protein, preferably a CARK protein, which is encoded by a nucleic acid molecule consisting of a nucleotide sequence at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 82%, 85%, 90%, 95%, 98% or more homologous to a nucleotide sequence of SEQ ID NO:1, 3, 7, or 9, or a complement thereof. This invention further features an isolated protein, preferably a CARK protein, which is encoded by a nucleic acid molecule consisting of a nucleotide sequence which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, 7, or 9, or a complement thereof. The proteins of the present invention or portions thereof, e.g., biologically active portions thereof, can be operatively linked to a non-CARK polypeptide (e.g., heterologous amino acid sequences) to form fusion proteins. The invention further features antibodies, such as monoclonal or polyclonal antibodies, that specifically bind proteins of the invention, preferably CARK proteins. In addition, the CARK proteins or biologically active portions thereof can be incorporated into pharmaceutical compositions, which optionally include pharmaceutically acceptable carriers. In another aspect, the present invention provides a method for detecting the presence of a CARK nucleic acid molecule, protein or polypeptide in a biological sample by contacting the biological sample with an agent capable of detecting a CARK nucleic acid molecule, protein or polypeptide such that the presence of a CARK nucleic acid molecule, protein or polypeptide is detected in the biological sample. In another aspect, the present invention provides a method for detecting the presence of CARK activity in a biological sample by contacting the biological sample with an agent capable of detecting an indicator of CARK activity such that the presence of CARK activity is detected in the biological sample. In another aspect, the invention provides a method for modulating CARK activity comprising contacting a cell capable of expressing CARK with an agent that modulates CARK activity such that CARK activity in the cell is modulated. In one embodiment, the agent inhibits CARK activity. In another embodiment, the agent stimulates CARK activity. In one embodiment, the agent is an antibody that specifically binds to a CARK protein. In another embodiment, the agent modulates expression of CARK by modulating transcription of a CARK gene or translation of a CARK mRNA. In yet another embodiment, the agent is a nucleic acid molecule having a nucleotide sequence that is antisense to the coding strand of a CARK mRNA or a CARK gene. In one embodiment, the methods of the present invention are used to treat a subject having a disorder characterized by aberrant or unwanted CARK protein or nucleic acid expression or activity by administering an agent which is a CARK modulator to the subject. In one embodiment, the CARK modulator is a CARK protein. In another embodiment the CARK modulator is a CARK nucleic acid molecule. In yet another embodiment, the CARK modulator is a peptide, peptidomimetic, or other small molecule. In a preferred embodiment, the disorder characterized by aberrant or unwanted CARK protein or nucleic acid expression is a cardiovascular disorder. The present invention also provides a diagnostic assay for identifying the presence or absence of a genetic alteration characterized by at least one of (i) aberrant modification or mutation of a gene encoding a CARK protein; (ii) mis-regulation of the gene; and (iii) aberrant post-translational modification of a CARK protein, wherein a wild-type form of the gene encodes a protein with a CARK activity. In another aspect the invention provides a method for identifying a compound that binds to or modulates the activity of a CARK protein, by providing an indicator composition comprising a CARK protein having CARK activity, contacting the indicator composition with a test compound, and determining the effect of the test compound on CARK activity in the indicator composition to identify a compound that modulates the activity of a CARK protein. Other features and advantages of the invention will be apparent from the following detailed description and claims. |
| PATENT EXAMPLES | This data is not available for free |
| PATENT PHOTOCOPY | Available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |